Virulence and Antibiotic Resistance of Acinetobacter baumannii among Urinary Tract Infections
| Autor: | Hussein O. M. Al-Dahmoshi, Noor S. K. Al-Khafaji, Farah Tareq Al-Alaq |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
0301 basic medicine
biology business.industry Urinary system InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL 030106 microbiology Virulence biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification Microbiology Acinetobacter baumannii 03 medical and health sciences 030104 developmental biology Antibiotic resistance polycyclic compounds bacteria Medicine business GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) |
| DOI: | 10.5772/intechopen.94508 |
| Popis: | Acinetobacter baumannii is one of the opportunistic bacteria firstly related with the hospital acquired infection influencing primarily to weakening the patient in the ICU. It is sometimes transferred to the patient by transient colonization of hands of the workers of healthcare, and persistence on eco-surfaces. Acinetobacter baumannii inhalation aerosolized through endo-tracheal suctioning of the ventilated patient is widespread among ventilator-related pneumonia (VAP). It is infections mainly associated with ventilator-related pneumonia (VAP), community Acquired Pneumonia (CAP), invasive bacterial infections (IBIs) and UTI (urinary tract infection). It is one of the prominent uropathogens problematic with antibiotic resistance especially carbapenem resistant Acinetobacter baumannii (CRAB). Their colonization of urinary tract and establishment of infection may attributed mainly to set of virulence factors like: Acinetobactin-assisted iron acquisition system, Bap (biofilm-related protein), phospholipase D, Ata (Acinetobacter trimeric autotransporter), chaperone-usher type pilus (Csu), OmpA (outer membrane protein A), and Plasminogen-binding protein (CipA). The common drugs used for treatment Acinetobacter baumannii infections involve polymyxins, glycylcyclines, tetracyclines, mono-bactams, fluoroquinolones, aminoglycosides, antipseudomonal carbapenems, antipseudomonal cephalosporins, and sulbactam. The rates of MDR isolation or also comprehensively the resistant Acinetobacter baumannii are significantly increased and so the combination of two or more (colistin, tigecycline, or colistin-rifampicin combination therapy) drugs is sometimes used to treat infections of MDR-AB. As a conclusion the Acinetobacter baumannii engagement in urinary tract infections attributed mainly to their adhesins, invasins and intrinsic antibiotic resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|